Company
Vetoquinol SA
Headquarters: Lure, France
Employees: 2,525
CEO: Mr. Matthieu Frechin
Market Cap
€804.5 Million
EUR as of Jan. 1, 2025
US$837.1 Million
Vetoquinol SA Categories
France Healthcare Drug Manufacturers—Specialty & GenericFrance Healthcare France Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | €537.5 M |
| EBITDA | €115.8 M |
| Gross Profit TTM | €287.4 M |
| Profit Margin | 8.77% |
| Operating Margin | 12.03% |
| Quarterly Revenue Growth | 3.20% |
Stocks & Indices
Vetoquinol SA has the following listings and related stock indices.
Stock: Euronext: VETO wb_incandescent
Stock: FSX: 8JM wb_incandescent